Shiming Zhang,Kit-Kay Mak,Anjani Uma Rani Mosalikanti et al.
Shiming Zhang et al.
Neuroinflammation contributes to many CNS disorders, whereas broad anti-inflammatory treatments can compromise host defenses. A20, encoded by TNFAIP3, is a ubiquitin-editing immunoregulatory protein that restrains NF-κB signaling. Beyond i...
From complexity to approval in the European Union: Regulatory pathways and data challenges in the evaluation of non-oncology orphan medicines [0.03%]
从复杂性到认可：欧洲药品评价孤儿药（非肿瘤）的监管途径和数据挑战
Gaёlle Andriantafika,Heidi Janssen,Ewa Balkowiec-Iskra et al.
Gaёlle Andriantafika et al.
Generating comprehensive evidence for regulatory evaluation of non-oncology orphan medicines (NOOMS) at the marketing authorisation stage remains challenging. We assessed patterns observed across NOOMS applications between 2006 and 2024 com...
Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets [0.03%]
估算临床药物研发退后项目的全球存量：面向搁置资产的市场构想
Annette Bakker,Tanisha Carino,Joonhyuk Cho et al.
Annette Bakker et al.
We propose a set of algorithms to identify 'shelved asset candidates' in drug development-drug candidates for which development was discontinued for reasons other than safety or efficacy. Using a variety of microdata sources and classificat...
Pai-Sheng Chen,Chiao Lo,Da-Liang Ou et al.
Pai-Sheng Chen et al.
Breast cancer therapy is limited by heterogeneous tumor states and adaptive resistance that may be missed by single-layer biomarkers. This review focuses on the clinically actionable integration of multi-omics in breast cancer, emphasizing ...
Major objections in EU medicines authorisation applications: an analysis of dossier submissions by small- and medium-sized enterprises [0.03%]
欧盟药品审批申请中的主要异议分析：小型及中型企业的案例研究
Eglantine Legros,Leonor Enes,Constantinos Ziogas
Eglantine Legros
XXX. Copyright © 2026 The Authors. Published by Elsevier Ltd.. All rights reserved.
Zebrafish swimming towards cures: a scalable NAM platform for drug discovery [0.03%]
斑马鱼向治愈疾病游来：药物发现的可扩展近交系平台
Veona Cutinho,Charles H Williams
Veona Cutinho
Drug discovery faces escalating costs, extended timelines, and ∼90% failure rates, prompting National Institutes of Health (NIH) and US Food and Drug Adminstration (FDA) guidance to reduce animal testing. As a New Approach Methodology (NAM...
Insight into human allogenic CAR-T therapy: an open-access dataset [0.03%]
人体同种异体CAR-T疗法的见解：一个开放获取的数据集
Natalia Obajtek,Bartek Lisowski,Seweryn Ulaszek et al.
Natalia Obajtek et al.
Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates significant efficacy in various cancers, predominantly as a subsequent treatment line following multiple prior therapies. When compared to autologous options, allogeneic CAR-T pr...
Revisiting risk-adjusted Net Present Value: a practical framework for biotechnology valuation [0.03%]
重新审视经风险调整的净现值：生物技术评估的实际框架
Ju Han Yeon,Chunkyu Kim,Heung-Sik Kang et al.
Ju Han Yeon et al.
Traditional risk-adjusted valuation methods in the biotechnology industry exhibit significant limitations when assessing early-stage technologies. These limitations include high failure rates, lengthy development timelines, and substantial ...
Alastair D G Lawson,Helene M Finney,Alexander Hillisch et al.
Alastair D G Lawson et al.
The Janus-faced suppressor of cytokine signaling 2-antisense transcript 1 in human cancers: from molecular mechanisms to clinical translation [0.03%]
人类癌症中的janus-faced细胞因子信号抑制剂2反义转录物1：从分子机制到临床转化
Shirui Lu,Fangteng Liu
Shirui Lu
Suppressor of cytokine signaling 2-antisense transcript 1 (SOCS2-AS1) is a long non-coding RNA transcribed from the antisense strand of SOCS2. Emerging evidence links its aberrant expression to clinical outcomes in multiple cancers. This wo...